An inhibitor of EGFR, afatinib is a second-generation small-molecule inhibitor that also targets the EGFR pathway NSCLC adenocarcinomas with activating EGFR mutations that are eligible for therapy with these drugs. Here, EGFR is linked to adenocarcinoma.